hero news banner

Scientific Publications

Foundational Science

Epilepsy

Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of γ8 Transmembrane AMPA Receptor Regulatory Protein (TARPγ8): Impact on RNS Long Episodes and Focal Seizures

William W. Motley, MD, D.Phil; Imran H. Quraishi, MD, PhD; Neal Nolan, MD; Daniel Friedman, MD; Patrick Landazuri, MD; Vikram…

Read Publications Now
RAP-219: A Differentiated ASM Targeting Restricted Brain Expression of γ8 Transmembrane AMPA Receptor Regulatory Protein (TARPγ8)

Stephen Greene, PharmD; Marie Cohilis, PhD; Michel Koole, PhD; Kim Serdons, PhD; Marissa Herbots, MSN; Kathleen Sierens, MD; Jan de…

Read Publications Now
Effect of RAP-219 on Long Episodes and Clinical Seizures in Adults With Drug-Resistant Focal Seizures and an Implanted Responsive Neurostimulator (RNS) System by Baseline Disease Severity: A Post-Hoc Analysis of a Phase 2a Proof-of-Concept Study

Neal M. Nolan, MD; Daniel Friedman, MD; William W. Motley, MD; Michael Gelfand, MD, PhD; Jeff Sevigny, MD; Patrick Landazuri,…

Read Publications Now
Effect of RAP-219 on Seizure Severity in Adults with Drug-Resistant Focal Onset Seizures and an Implanted Responsive Neurostimulator (RNS) System: Analysis of a Phase 2a Proof-of-Concept Study

Arnold R. Gammaitoni, PharmD; Jacqueline A. French, MD; Neal M. Nolan, MD; Allison Little, PharmD; Taneeta M. Ganguly, MD; Shiling…

Read Publications Now
Safety, Tolerability, and Pharmacokinetics of RAP-219 in Healthy Volunteers

Swamy Yeleswaram, PhD; Bradley S. Galer, MD; William W. Motley, MD; Stephen Greene, PharmD

Read Publications Now
Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219, a Negative Allosteric Modulator of the γ8 Transmembrane AMPA Receptor-Associated Regulatory Protein (TARPγ8)

William W. Motley, MD; Daniel Friedman, MD; Kathryn A. Davis, MD; Bradley S. Galer, MD; Nancy Wyant, BA; Jose A….

Read Publications Now
Optimal Cut Point for Reduction in Long Episode Frequency to Predict Meaningful Change in Clinical Seizure Frequency

Arnold R. Gammaitoni, PharmD; Martha J. Morrell, MD; Jacqueline A. French, MD; Daniel Friedman, MD; Kathryn A. Davis, MD; Thomas…

Read Publications Now
Evolution of RAP-219 for the Treatment of Epilepsy
Read Publications Now
RAP-219 a Novel, Potent, and Selective Negative Modulator of AMPAR/TARPγ8

Arnold Gammaitoni, Pharm.D. SVP, Medical Affairs, Rapport Therapeutics

Read Publications Now
Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219, a Negative Allosteric Modulator of the γ8 Transmembrane AMPA Receptor Associated Protein (TARPγ8)

Jose A. Matta, PhD, Weston Davini, MS, Laurie P. Volak, PhD, Brock T. Shireman, PhD, and David Bredt, MD, PhD

Read Publications Now
Early detection rate changes from a brain-responsive neurostimulation system predict efficacy of newly added antiseizure drugs

Quraishi et al, Epilepsia (2019) 61:138–148

Read Publications Now
How do we choose the appropriate animal model for antiseizure therapy development?

Barker-Haliski et al, EXPERT OPINION ON DRUG DISCOVERY (2019) 10: 947–951

Read Publications Now
Clinical and electrocorticographic response to antiepileptic drugs in patients treated with responsive stimulation

Skarpass, et al, Epilepsy & Behavior (2018) 83: 192–200

Read Publications Now

Pain

Hearing/Vestibular Disorders